Background: IgA nephropathy is the most common primary glomerulonephritis in pregnancy and shares with other immunologic diseases and kidney diseases a relationship with adverse maternal outcomes, whose entity and pattern is only partially quantified. Recent studies provide new information and a systematic review regarded progression of kidney disease. The discussion of the outcomes with respect to low-risk pregnancies may help to perfect the estimation of the risks, and to identify specific research needs. Methods: A search strategy was built on Medline, EMBASE and the Cochrane review for the period January 2000-April 2017, aimed at retrieving both case series (defined as with at least 6 pregnancies in women with IgA nephropathy) and case reports, to look into rare occurrences. All papers, with or without control groups, were selected if they reported on at least one pregnancy outcome, or on long-term kidney function. Search strategy, paper selection and data extraction were done in duplicate (PROSPERO N 42016042623). Meta-analysis of case series was performed with Metanalyst Beta 3.13. Case reports were analysed narratively. Results: The search retrieved 556 papers, of which 27 were included (13 series and 14 case-reports). The case series report on 581 women with 729 pregnancies. The analysis was performed in comparison to the available control groups: 562 non-pregnant controls were available for the analysis of progression of kidney disease. As for pregnancy related outcomes (preeclampsia (PE), pregnancy induced hypertension (PIH), preterm birth, small babies), we meta-analyzed the data with respect to the only series of low-risk pregnancies (1418 pregnancies). When compared with women who never got pregnant after diagnosis of IgA nephropathy, in the present meta-analysis pregnancy in women with IgA nephropathy was not associated with a higher risk of progression of kidney disease, possibly due to the overall preserved kidney function at baseline: end-stage kidney disease (OR 0.68; CI 0.28-1.65). Conversely, the incidence of adverse pregnancy-related outcomes was increased compared to low-risk controls: PE and PIH were more than ten-fold increased (OR 11.80;, while the increase in risk of preterm birth and "low birth weight babies" was less marked (OR 3.37; CI 1.91-5.95 and OR 2.36; CI 1.52-3.66), a discrepancy suggesting the occurrence of "late" or "maternal" PE, that may affect less severely foetal growth or shorten gestation. In conclusion, in the present meta-analysis IgA nephropathy was not associated with an increased progression of kidney disease. The more than ten-fold increased risk of PIH and PE, in combination with a doubled
Introduction
IgA nephropathy is probably the most common primary glomerular nephritis worldwide; its higher incidence in young people makes it highly relevant in pregnancy [1] .
The present term of IgA nephropathy encompasses two previously defined diseases, usually known by their eponyms: Berger's disease, in which the IgA deposition is limited to the kidney, and Henoch-Shönlein, in which IgA nephropathy is a part of a systemic vasculitis that could involve the skin and the gastro-intestinal tract, with asymmetric acute osteoarthritis [2, 3] . The recognition of family clustering of the two diseases, and the identical renal pathology led to gather both diseases under a unifying definition [4] [5] [6] . IgA nephropathy may present with a wide spectrum of clinical presentations, from mild, recurrent and remittent microhematuria to boosts of macrohematuria and nephritic syndrome, or a severe and rapidly progressive disease [1, 4, 7, 8] . Hypertension and proteinuria are considered as negative outcome predictors, even if only mild. Their negative effect on outcome is observed even in the absence of reduced renal function, which is a likewise (albeit tautological) acknowledged progression marker itself. Other histological markers of disease progression and risk are still subject of debate [7] [8] [9] [10] [11] [12] [13] [14] . The risk of progression to end stage renal disease (ESRD) has been differently evaluated. However, this risk is not negligible over the entire life span as progression to ERSD is reported from rare to frequent, depending on morphological, clinical and laboratory characteristics, and treatment. For these reasons, IgA nephropathy is usually considered as a disease that may remit, but that is never completely cured [14] [15] [16] [17] [18] .
The acknowledgement of the importance of early renal disease in pregnancy is particularly relevant for IgA nephropathy, due to its relatively high prevalence in young age, slow progression, with frequent preservation of the kidney function at least for long periods, making normal kidney function common in affected patients in childbearing age, and heterogeneous presentation, that may impair early diagnosis [19] [20] [21] [22] .
As will be further discussed in detail, a systematic review, encompassing a wide time span, was recently focused on the progression of chronic kidney disease in patients with IgA nephropathy who had been pregnant [23] . To try to further add to the knowledge in this important field, we considered several recent publications, not available at the time of the first review, and we focused a second systematic review on the effect of IgA nephropathy on pregnancy and of pregnancy on the progression of IgA nephropathy, on the new millennium, on the account of the changes in disease management and maternofetal care occurring over time, and we attempted for the first time a meta-analytical comparison with a low-risk population, in order to better quantify the risk of the various adverse pregnancy outcomes, as a further support for counseling.
Methods

Eligibility Criteria
The eligibility criteria were broad, because of the expected retrieval of heterogeneous designs and definitions. Consequently, we included all published studies that dealt with IgA nephropathy in pregnancy and that reported on at least one pregnancy-related outcome, or on long-term kidney function. We included all study designs, i.e., prospective or retrospective cohort studies, case-control studies, trial-based analyses, and case reports. Reviews, whether or not systematic, were also gathered to check for papers eventually escaped from our wide search strategy. The search was not limited to papers which provided a control group, but information on all control groups were gathered.
Studies were divided into those regarding more than 5 or less than 6 cases (defined as case series and cases reports, respectively).
The review was prospectively registered on PROSPERO International prospective register of systematic reviews (N 42016042623).
The review was performed according to the Meta-analysis of observational studies in epidemiology (MOOSE) criteria.
Search Strategy
We searched MEDLINE, PubMed, Embase and the Cochrane Review database from January 2000 to April 30th 2017 using a combination of MeSH terms and keywords related to IgA nephropathy and pregnancy, including: pregnancy, pregnant, gestation* and IgA nephropathy, Henoch* or Shoenlein*, Berger*. We also checked the reference lists of relevant articles and citations of included studies.
We did not limit our search to any language, but we limited it to the period starting from 2000, allowing for the considerable changes in management of the disease and in maternofetal follow-up that occurred in the new millennium, in order to implement the clinical decision rules presently recommended by the very few guidelines or consensus statements dealing with glomerular diseases in pregnancy [24] [25] [26] .
All articles identified were screened for eligibility on the basis of the content only: all papers reporting on any form of IgA nephropathy in pregnancy and reporting on any outcome were selected. The search was performed by G.B.P. and I.A.K., after which I.A.K. and R.A. did a first screening of the papers. The final selection was agreed between G.B.P. and I.A.K., any discrepancy was resolved by discussion.
Data Extraction and Quality Assessment
Two reviewers (I.A.K. and G.B.P.) extracted study and population characteristics and outcomes. A third reviewer (G.C.) double-checked the accuracy of data entered from each study in case of discrepancies. All definitions of IgA nephropathy, pre-eclampsia (PE), pregnancy induced hypertension (PIH), small babies, small for gestational age babies (SGA) or other pregnancy related outcomes were gathered.
Due to the lack of randomized controlled trials (RCTs), and to the limited number and type of control groups, no formal analysis of risk of bias was performed. No selection for quality was performed. However, the studies were critically analyzed and the completeness of the data was considered as an indirect marker of quality.
The case series were compared with the controls available, regarding progression of chronic kidney disease (CKD), and with the only low risk population available, regarding the various pregnancy outcomes. Odds ratios and confidence intervals were calculated (OR, CI). The case reports were described narratively.
Data Synthesis
The PICOS criteria were adapted to this particular situation in which pregnancy is considered the "intervention" as follows:
P-Patients: women with IgA nephropathy in pregnancy; I-Intervention: in the absence of a true "intervention", pregnancy was considered as the "intervention"; C-Comparators: in the case of progression of kidney disease, non-pregnant IgA patients were considered as comparators. In the case of pregnancy outcomes, considered low-risk pregnancies or pregnancies in women not affected by IgA nephropathy (or other kidney diseases); O-Outcomes: progression of kidney disease; all the materno-fetal outcomes described in the papers (including, but not limited to, PE, PIH, preterm delivery, small babies, SGA).
S-Studies: all studies, regardless of the study design, reporting on pregnancy outcomes or on long-term kidney function in patients with IgA nephropathy.
Statistical analysis was performed using Metanalyst Beta 3.13. Due to the high baseline heterogeneity a random effect model was employed. Stratification for baseline renal function, hypertension and proteinuria was attempted, but was not possible due to the high heterogeneity of the papers.
The control groups retrieved mainly regarded progression of kidney disease in women with IgA nephropathy who did not get pregnant after diagnosis; these data were used to analyze the effect of pregnancy on kidney function.
For pregnancy-related outcomes, we employed as a control group the only low-risk population available (from the cohort named TOCOS from the Torino Cagliari Observational Study) and meta-analyzed each study with respect to it.
Results
Case Series: Overall Data
The search strategy identified 556 articles, of which 27 met the inclusion criteria: 13 case series, which we attempted to meta-analyze, for the various outcomes, and 14 case reports, discussed narratively ( Figure 1 ) .
O-Outcomes: progression of kidney disease; all the materno-fetal outcomes described in the papers (including, but not limited to, PE, PIH, preterm delivery, small babies, SGA).
Results
Case Series: Overall Data
The search strategy identified 556 articles, of which 27 met the inclusion criteria: 13 case series, which we attempted to meta-analyze, for the various outcomes, and 14 case reports, discussed narratively ( Figure 1 ) . The main characteristics of the case series are reported in Tables 1-4 [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . Overall, the case series included four prospective studies, eight retrospective studies and two matched cohort studies, the latter regarding progression of CKD in women affected by IgA nephropathy, with or without pregnancy (Table 1) . Globally, the studies report on 581 women with 729 pregnancies in IgA nephropathy (assuming one pregnancy per woman if not otherwise specified), and on 562 non-pregnant controls distributed over three studies; conversely, normal pregnancies were available in only one study [30] .
The studies are heterogeneous for the number of pregnancies (12 to 229), setting of study (seven from Asia, five from Europe, one from the USA and one from Saudi Arabia), and study aims. Six studies provided information on the type and frequency of control policies in pregnancy and during follow-up ( Table 2 ). Table 3 reports on the main pregnancy-related outcomes reported in the papers. Given the different study designs, the included studies reported on different outcomes: neonatal deaths were reported on by 4 studies, live births were reported on by 8 studies, preterm delivery was reported by 8, and need for admission to neonatal intensive care unit by one study only. All studies reported on preeclampsia (PE) and/or hypertensive disorders of pregnancy. Information on birth weight was available in most studies, but the information was not always contextualized to gestational age, and the information on neonates small for gestational age was available in two studies only.
Case Series: Pregnancy Outcomes
Overall, the papers describe a population with high incidence of PIH (reported in around 30% of the cases, however, the distinction with preexisting hypertension is usually lacking, and this leads to a possible underestimation of new onset hypertension) and PE (reported in around 15% of the cases), with about 15% incidence of preterm deliveries, usually without exhaustive specification of gestational age (Table 3) . Table 4 reports on baseline kidney function and other maternal outcomes: baseline kidney function (glomerular filtration rate: GFR) was relatively well preserved in most studies but was fully normal in 2 only (GFR was >100 mL/min in 2 studies and <100 mL/min in 7 studies). Mean proteinuria was around 1 g/day. Prevalence of hypertension was not clearly defined at baseline, and the distinction between previous use of angiotensin converting enzyme-inhibitors (ACEi) or Angiotensin II receptor blockers (ARBS) for proteinuria, hypertension or both was not available.
Four of five studies reporting on kidney function over time did not find any difference between cases and non-pregnant controls during follow-up, considering however different outcomes (start of dialysis, doubling of serum creatinine, GFR decrease, new-onset hypertension); the fifth, most recent study, found a correlation between kidney function worsening and the occurrence of adverse pregnancy outcomes [27] (Table 4 ).
Case Reports
The main characteristics of the case reports are summarized in Tables 5-7 [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] . Keeping in mind the aim to discuss severe or unusual situations, the cases reported on various situations, including new onset-diagnosis of IgA nephropathy in pregnancy, recurrence of IgA nephropathy in a kidney allograft, severe reduction of the kidney function (5 cases); one case reported on three pregnancies in the same woman (one occurring in the pre-dialysis phase, two on dialysis) ( Table 5) .
Presumably as a consequence of the different selection of the cases compared to that of the series, most of the babies were born preterm (61.5%); maternal complications were common (30%) and more than half of the newborns had low birth weight. Nevertheless, all reported babies had a favorable outcome. Conversely, dialysis was needed in pregnancy in three cases and half of the patients developed hypertension or preeclampsia. Summary data baseline GFR or CCr >100 mL/min in 2/9 study reporting on this item GFR <100 mL/min in 7/9 studies PtU ≥0.5 g/day in 6/7; <0.5 g /day in 1/7 studies (**) Hypertension in 11-61% in 4 studies, in other not clearly defined at baseline Summary data progression ESRD: 11/330 (3.3%) cases vs 22/458 (4.8%) controls, reported on by 5 studies of whom 3 provided a control group § Park: no significant difference between cases and non-pregnant controls. Significant better renal survival in cases without vs with obstetric complications, and in cases without obstetric complications vs non pregnant controls Su: no significant difference in incidence ESRD or eGFR decrease between cases and non-pregnant controls Liu: no difference between cases and non-pregnant controls over follow-up Shimizu: no difference in eGFR decrease between pregnancy and non-pregnancy Limardo: no significant difference in all outcomes (start of dialysis, doubling of serum creatinine, new onset hypertension)
BP: blood pressure; CCr: creatinine clearance; (e)GFR: (estimated) glomerular filtration rate; ESRD: end-stage renal disease; HT: hypertension; MAP: mean arterial pressure; NR: not reported; P: pregnancies; PE: preeclampsia; PtU: proteinuria; sCr: serum creatinine. * Abstract only (*) article in Japanese, abstract used. ** discrepant data between the various CKD stages and overall, as for proteinuria: Overall: 0.86 ± 0.80-0.56 ± 0.48. § used in meta-analysis despite of difference in follow-up (1 to 10 years); § § not mentioned in article, additional information available in original database. AGA: appropriate for gestational age; CS: cesarean; d: days; F: female; Gravi: gravidity; GW: Week of gestation; h: hours; HT: hypertension;
LGA: large for gestational age; M: male; m: months; Multi: multipara; NICU: neonatal intensive care unit; NR: not reported; Para/P: parity; PE: preeclampsia; Primi: primipara; Pts: Patients; RD: respiratory distress; w: weeks. * Abstract only (*) abstract used * Centiles calculated according to the INeS charts (reference). If parity or sex are not specified: male sex and primipara considered. 
Meta-Analysis
Kidney Function Figure 2 reports on ESRD and the start of renal replacement therapy in patients with and without pregnancy. The incidence was low in the five studies reporting on this outcome: 11/330 patients versus 22/458 controls, and there was no significant difference found between the two groups (OR 0.68; CI 0.28-1.65).
Kidney function Figure 2 reports on ESRD and the start of renal replacement therapy in patients with and without pregnancy. The incidence was low in the five studies reporting on this outcome: 11/330 patients versus 22/458 controls, and there was no significant difference found between the two groups (OR 0.68; CI 0.28-1.65). These reassuring data have to be contextualized to patients with good renal function, and it has to be taken into account that time of follow up differed notably between the studies (ranging from 1 to 10 years postpartum), which reduces the clinical value of this comparison ( Figure 2 ).
Pregnancy Related Outcomes
The risk for adverse pregnancy-related outcomes was higher in IgA patients than in the low-risk cohort (Figure 3) .
While the incidence of caesarean sections and the incidence of small for gestational age babies were not significantly different in IgA nephropathy and in the low-risk control group, the odds ratio for preterm delivery, PE and PIH were significantly higher for women with IgA nephropathy (Figure 3 These reassuring data have to be contextualized to patients with good renal function, and it has to be taken into account that time of follow up differed notably between the studies (ranging from 1 to 10 years postpartum), which reduces the clinical value of this comparison ( Figure 2 ).
While the incidence of caesarean sections and the incidence of small for gestational age babies were not significantly different in IgA nephropathy and in the low-risk control group, the odds ratio for preterm delivery, PE and PIH were significantly higher for women with IgA nephropathy (Figure 3 
Discussion
This systematic review identified 13 cases series and 14 case reports, reporting on pregnancy-related outcomes in IgA nephropathy . This is, at the best of our knowledge, the largest number of papers meta-analyzed or narratively discussed on IgA nephropathy in pregnancy, 
This systematic review identified 13 cases series and 14 case reports, reporting on pregnancy-related outcomes in IgA nephropathy . This is, at the best of our knowledge, the largest number of papers meta-analyzed or narratively discussed on IgA nephropathy in pregnancy, with particular attention to the risk of adverse pregnancy-related outcomes. In this regard, our review may add information to a previous recent systematic review, which included papers published since the start of Medline, and was mainly focused on the progression of kidney disease in patients with IgA nephropathy with and without pregnancy [23] . The review, that selected 4 papers with a control group, providing data of 273 patients with IgA nephropathy and of 241 patients with IgA nephropathy who did not become pregnant, supported a lack of disadvantage on the progression of nephropathy for IgA nephropathy patients with well-preserved function that became pregnant.
The main novelty of the present review is to give more insight into the risk of pregnancy-related outcomes, that were already reported as frequent by the previous study, but that are meta-analyzed for the first time with respect to a low-risk population; in this context, limiting the analysis to the studies published since 2000 may allow for a better contextualization in the present panorama (Figure 3) .
The pattern of pregnancy-related outcomes is complex and the behavior of the risks may offer some interesting insights into the pathogenesis of pregnancy complications in IgA nephropathy. In fact, the meta-analysis identifies a particularly high risk of PE and PIH in women with IgA nephropathy, with an over ten-fold increase, within wide but consistent confidence intervals (Figure 3) . In spite of these high odds ratios, the significantly increased risk of preterm birth was only about triple compared to the low-risk population and the incidence of newborns with low birth weight is only doubled, while no difference was found in the incidence of both caesarean sections and of small for gestational age babies (Figure 3 ). This finding suggests that the very high risk for hypertensive disorders of pregnancy is not accompanied by a correspondent increase of preterm babies, and of babies whose growth has been severely impaired, as it occurs in the "placental" early forms of preeclampsia, and therefore suggests that the related event occurs later, corresponding with the so-called "late" form of PE [54] [55] [56] [57] [58] . Such a form of PE is usually milder, and is often associated with maternal diseases, and indeed some authors distinguish between "maternal" and "placental" preeclampsia, the latter characterized by a primary defect of placentation, and frequently associated with intrauterine growth restriction. Conversely, the maternal form is more often of late onset, frequently, even if not always, less severe, and is associated with a lower risk of newborns that are small for gestational age, a pattern that may be consistent with the observations gathered in the present review [54] [55] [56] [57] [58] [59] .
With respect to disease progression, the lack of negative effect of pregnancy, at least in populations with relatively preserved kidney function, reported in the previous meta-analysis, is confirmed by our analysis, performed with a different, selection of the papers, and with the chance of adding several recent studies on this issue (Figure 2 ) [23] . In most of the studies retrieved by both reviews kidney function was normal or well-preserved before pregnancy and, in this context, the progression of the kidney disease does not appear to be affected by pregnancy. However, most studies fail to give information both on women with severe CKD and the duration of the observation time is not always clear. Furthermore, even if relatively long, the median follow-up period of 10 years described by Limardo, and of 4.5 years by Liu, could still be too short to draw conclusions, given the slow progression of early IgA nephropathy [31, 36] . The interesting new suggestion that progression of kidney disease is limited to the cases who display adverse pregnancy outcomes should be confirmed in further studies [27] .
The case reports, as expected, focus on exceptional events, and are probably affected by reporting and publishing biases. Despite these limits, they may underline that positive pregnancy outcomes are possible, even in severe advanced chronic kidney disease [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] (Tables 5-7) .
The major strength of this study is that it provides an updated systematic review in one of the most common nephropathies observed in young patients all over the world, gathering over 700 pregnancy published in the new millennium, and attempting, for the first time, a risk assessment with regard to the overall population. The integration with case reports, a further novel aspect of this review, underlines that a positive outcome is possible even in women with severe CKD, who are usually excluded from the larger case series.
The main limitations of this review are linked to the heterogeneity of the studies in terms of populations, definitions and outcomes, as well as duration of follow-up. Heterogeneity is a common problem in systematic reviews on CKD pregnancies, which limits the value of the meta-analysis, and calls for a common language, a still unmet goal [60] [61] [62] . Furthermore, due to lack of data on low-risk populations, we employed the only available one, from a multicenter Italian study; the approach of choosing a reference population for a wider meta-analysis is not new, and was for example employed by Deshpande and coworkers in the pivotal analysis on pregnancy after kidney or after liver transplantation, which plotted the data against the reference USA population [63, 64] . Such a choice is an obvious compromise, and the lack of matched populations limits the precision of the comparison; however, the differences with the low-risk populations are highly significant, and their pattern is consistent, thus allowing at least posing new hypotheses and indications for future research.
Within these limits, we hope that our findings may be of interest for counseling and for tailoring clinical surveillance for clinicians working in obstetrics and in nephrology.
Our study may also indicate uncovered fields for future research. First of all, more data is needed to better define the risk of adverse pregnancy outcomes, particularly so in case of kidney function decrease. Secondly, given the impossibility to clinically distinguish an increase in proteinuria and hypertension related to the IgA nephropathy from that related to preeclampsia, there is need for precise description of these cases, with stratification for previous hypertension, and univocal definitions of superimposed PE. In this regard, IgA nephropathy may represent a field for the systematic use of old and new biomarkers of PE and kidney disease [63] [64] [65] [66] [67] [68] .
Conclusions
Patients with IgA nephropathy and severe CKD should be informed about the paucity of data allowing a precise quantification of the risks. In patients with preserved kidney function, that represent the majority of those reported, the risk of progression of kidney disease is low, and may be limited to the cases who display adverse pregnancy related events. Conversely the risk of developing PE and PIH is very high compared to the low-risk population (OR > 10). The pattern of these hypertensive disorders of pregnancy, associated with a significant but milder increase in preterm delivery but not of small for gestational age babies, suggests the presence of late onset PE, in its "maternal" form, thought to affect fetal growth less severely than 'placental' early PE. This hypothesis, needing confirmation on a larger scale, may prove of interest in interpreting the increase in hypertensive disorders of pregnancy observed in chronic kidney disease.
